Your request to link to rcsb for Protease
- 1C6X: alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in 80's loop. (10.1107/S0907444900000469 )
- 1C6Y: alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in 80's loop. (10.1107/S0907444900000469 )
- 1C6Z: alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in 80's loop. (10.1107/S0907444900000469 )
- 1C70: alternate binding site for the p1-p3 group of a class of potent hiv-1 protease inhibitors as a result of concerted structural change in 80's loop. (10.1107/S0907444900000469 )
- 1CPI: regioselective structural and functional mimicry of peptides. design of hydrolytically stable cyclic peptidomimetic inhibitors of hiv-1 protease
- 1D4H: hiv-1 protease in complex with the inhibitor bea435 (10.1046/J.1432-1033.2003.03533.X )
- 1D4I: hiv-1 protease in complex with the inhibitor bea425 (10.1046/J.1432-1033.2003.03533.X )
- 1D4J: hiv-1 protease in complex with the inhibitor msl370 (10.1046/J.1432-1033.2003.03533.X )
- 1D4K: hiv-1 protease complexed with a macrocyclic peptidomimetic inhibitor (10.1021/JM000013N )
- 1D4L: hiv-1 protease complexed with a macrocyclic peptidomimetic inhibitor (10.1021/JM000013N )
- 1D4S: hiv-1 protease v82f/i84v double mutant/tipranavir complex (10.1021/JM960541S )
- 1D4Y: hiv-1 protease triple mutant/tipranavir complex (10.1021/JM960541S )
- 1DAZ: structural and kinetic analysis of drug resistant mutants of hiv-1 protease (10.1046/J.1432-1327.1999.00514.X )
- 1DIF: hiv-1 protease in complex with a difluoroketone containing inhibitor a79285 (10.1006/JMBI.1996.0026 )
- 1DMP: structure of hiv-1 protease complex (10.1016/S1074-5521(96)90110-6 )
- 1DW6: structural and kinetic analysis of drug resistant mutants of hiv-1 protease (10.1046/J.1432-1327.1999.00514.X )
- 1EBK: structural and kinetic analysis of drug resistant mutants of hiv-1 protease (10.1046/J.1432-1327.1999.00514.X )
- 1EBW: hiv-1 protease in complex with the inhibitor bea322 (10.1046/J.1432-1033.2003.03533.X )
- 1EBY: hiv-1 protease in complex with the inhibitor bea369 (10.1046/J.1432-1033.2003.03533.X )
- 1EBZ: hiv-1 protease in complex with the inhibitor bea388 (10.1046/J.1432-1033.2003.03533.X )
- 1EC0: hiv-1 protease in complex with the inhibitor bea403 (10.1111/J.1432-1033.2004.04431.X )
- 1EC1: hiv-1 protease in complex with the inhibitor bea409 (10.1046/J.1432-1033.2003.03533.X )
- 1EC2: hiv-1 protease in complex with the inhibitor bea428 (10.1046/J.1432-1033.2003.03533.X )
- 1EC3: hiv-1 protease in complex with the inhibitor msa367 (10.1046/J.1432-1033.2003.03533.X )
- 1F7A: how does a symmetric dimer recognize an asymmetric substrate? a substrate complex of hiv-1 protease. (10.1006/JMBI.2000.4018 )
- 1FB7: crystal structure of an in vivo hiv-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance
- 1FEJ: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes (10.1002/PROT.1057 )
- 1FF0: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes. (10.1002/PROT.1057 )
- 1FFF: structural implications of drug resistant mutants of hiv-1 protease : high resolution crystal structures of the mutant protease/substrate analog complexes. (10.1002/PROT.1057 )
- 1FFI: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes (10.1002/PROT.1057 )
- 1FG6: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes (10.1002/PROT.1057 )
- 1FG8: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes (10.1002/PROT.1057 )
- 1FGC: structural implications of drug resistant mutants of hiv-1 protease: high resolution crystal structures of the mutant protease/substrate analog complexes (10.1002/PROT.1057 )
- 1FQX: crystal structure of the complex of hiv-1 protease with a peptidomimetic inhibitor (10.1107/S0907444900018928 )
- 1G2K: hiv-1 protease with cyclic sulfamide inhibitor, aha047 (10.1021/JM001024J )
- 1G35: crystal structure of hiv-1 protease in complex with inhibitor, aha024 (10.1021/JM001024J )
- 1GNM: hiv-1 protease mutant with val 82 replaced by asp (v82d) complexed with u89360e (inhibitor) (10.1021/BI960481S )
- 1GNN: hiv-1 protease mutant with val 82 replaced by asn (v82n) complexed with u89360e (inhibitor) (10.1021/BI960481S )
- 1GNO: hiv-1 protease (wild type) complexed with u89360e (inhibitor) (10.1021/BI960481S )
- 1HBV: a check on rational drug design. crystal structure of a complex of hiv-1 protease with a novel gamma-turn mimetic (10.1021/JM00017A008 )
- 1HEF: the crystal structures at 2.2 angstroms resolution of hydroxyethylene- based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
- 1HEG: the crystal structures at 2.2 angstroms resolution of hydroxyethylene- based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations
- 1HHP: the three-dimensional structure of the aspartyl protease from the hiv- 1 isolate bru (10.1016/0300-9084(91)90169-2 )
- 1HIH: comparative analysis of the x-ray structures of hiv-1 and hiv-2 proteases in complex with cgp 53820, a novel pseudosymmetric inhibitor (10.1016/S0969-2126(01)00169-1 )
- 1HIV: crystal structure of a complex of hiv-1 protease with a dihydroethylene-containing inhibitor: comparisons with molecular modeling
- 1HOS: inhibition of human immunodeficiency virus-1 protease by a c2- symmetric phosphinate synthesis and crystallographic analysis (10.1021/BI00082A019 )
- 1HPO: hiv-1 protease triple mutant/u103265 complex (10.1021/JM960441M )
- 1HPS: rational design, synthesis and crystallographic analysis of a hydroxyethylene-based hiv-1 protease inhibitor containing a heterocyclic p1'-p2' amide bond isostere (10.1021/JM00045A015 )
- 1HPV: crystal structure of hiv-1 protease in complex with vx-478, a potent and orally bioavailable inhibitor of the enzyme
- 1HPX: hiv-1 protease complexed with the inhibitor kni-272 (10.1016/S0969-2126(01)00192-7 )
- 1HSG: crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (hiv) ii protease complexed with l- 735,524, an orally bioavailable inhibitor of the hiv proteases
- 1HTE: x-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease (10.1021/BI00194A005 )
- 1HTF: x-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease (10.1021/BI00194A005 )
- 1HTG: x-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of hiv-1 protease (10.1021/BI00194A005 )
- 1HVH: nonpeptide cyclic cyanoguanidines as hiv protease inhibitors (10.1021/JM970524I )
- 1HVI: influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease
- 1HVJ: influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease
- 1HVK: influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease
- 1HVL: influence of stereochemistry on activity and binding modes for c2 symmetry-based diol inhibitors of hiv-1 protease
- 1HVR: rational design of potent, bioavailable, nonpeptide cyclic ureas as hiv protease inhibitors
- 1HVS: structural basis of drug resistance for the v82a mutant of hiv-1 protease: backbone flexibility and subsite repacking (10.1038/NSB0395-244 )
- 1HWR: molecular recognition of cyclic urea hiv protease inhibitors (10.1074/JBC.273.20.12325 )
- 1HXB: hiv-1 proteinase complexed with ro 31-8959 (10.1021/JM00115A028 )
- 1HXW: hiv-1 protease dimer complexed with a-84538 (10.1073/PNAS.92.7.2484 )
- 1IIQ: crystal structure of hiv-1 protease complexed with a hydroxyethylamine peptidomimetic inhibitor (10.1021/JM010979E )
- 1IZH: inhibitor of hiv protease with unusual binding mode potently inhibiting multi-resistant protease mutants (10.1016/S0022-2836(02)01139-7 )
- 1IZI: inhibitor of hiv protease with unusual binding mode potently inhibiting multi-resistant protease mutants (10.1016/S0022-2836(02)01139-7 )
- 1K1T: combining mutations in hiv-1 protease to understand mechanisms of resistance (10.1002/PROT.10140 )
- 1K1U: combining mutations in hiv-1 protease to understand mechanisms of resistance (10.1002/PROT.10140 )
- 1K2B: combining mutations in hiv-1 protease to understand mechanisms of resistance (10.1002/PROT.10140 )
- 1K2C: combining mutations in hiv-1 protease to understand mechanisms of resistance (10.1002/PROT.10140 )
- 1K6C: lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease (10.1110/PS.2520102 )
- 1K6P: lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease (10.1110/PS.2520102 )
- 1K6T: lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease (10.1110/PS.2520102 )
- 1K6V: lack of synergy for inhibitors targeting a multi-drug resistant hiv-1 protease (10.1110/PS.2520102 )
- 1KJ4: substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes (10.1016/S0969-2126(02)00720-7 )
- 1KJ7: substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes (10.1016/S0969-2126(02)00720-7 )
- 1KJF: substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes (10.1016/S0969-2126(02)00720-7 )
- 1KJG: substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes (10.1016/S0969-2126(02)00720-7 )
- 1KJH: substrate shape determines specificity of recognition recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes (10.1016/S0969-2126(02)00720-7 )
- 1KZK: je-2147-hiv protease complex (10.1021/BI011781Z )
- 1LZQ: crystal structure of the complex of mutant hiv-1 protease (a71v, v82t, i84v) with an ethylenamine peptidomimetic inhibitor boc-phe- psi[ch2ch2nh]-phe-glu-phe-nh2 (10.1021/JM021079G )
- 1M0B: hiv-1 protease in complex with an ethyleneamine inhibitor (10.1111/J.1432-1033.2004.04384.X )
- 1MER: hiv-1 mutant (i84v) protease complexed with dmp450 (10.1021/BI962234U )
- 1MES: hiv-1 mutant (i84v) protease complexed with dmp323 (10.1021/BI962234U )
- 1MET: hiv-1 mutant (v82f) protease complexed with dmp323 (10.1021/BI962234U )
- 1MEU: hiv-1 mutant (v82f, i84v) protease complexed with dmp323 (10.1021/BI962234U )
- 1MRW: structure of hiv protease (mutant q7k l33i l63i) complexed with kni- 577 (10.1002/PROT.20069 )
- 1MRX: structure of hiv protease (mutant q7k l33i l63i v82f i84v ) complexed with kni-577 (10.1002/PROT.20069 )
- 1MSM: the hiv protease (mutant q7k l33i l63i) complexed with kni-764 (an inhibitor) (10.1002/PROT.20069 )
- 1MSN: the hiv protease (mutant q7k l33i l63i v82f i84v) complexed with kni- 764 (an inhibitor) (10.1002/PROT.20069 )
- 1MTB: viability of a drug-resistant hiv-1 protease mutant: structural insights for better antiviral therapy (10.1128/JVI.77.2.1306-1315.2003 )
- 1MTR: hiv-1 protease complexed with a cyclic phe-ile-val peptidomimetic inhibitor
- 1MUI: crystal structure of hiv-1 protease complexed with lopinavir. (10.1016/S0968-0896(02)00051-2 )
- 1NH0: 1.03 a structure of hiv-1 protease: inhibitor binding inside and outside the active site (10.1021/JM031105Q )
- 1NPA: crystal structure of hiv-1 protease-hup (10.1021/JM970195U )
- 1NPV: crystal structure of hiv-1 protease complexed with ldc271 (10.1021/JM0204587 )
- 1NPW: crystal structure of hiv protease complexed with lgz479 (10.1021/JM0204587 )
- 1ODW: native hiv-1 proteinase
- 1ODX: hiv-1 proteinase mutant a71t, v82a
- 1ODY: hiv-1 protease complexed with an inhibitor lp-130
- 1OHR: viracept (r) (nelfinavir mesylate, ag1343): a potent orally bioavailable inhibitor of hiv-1 protease (10.1021/JM9704098 )
- 1PRO: hiv-1 protease dimer complexed with a-98881 (10.1021/JM9507183 )
- 1Q9P: solution structure of the mature hiv-1 protease monomer (10.1074/JBC.M307549200 )
- 1QBR: hiv-1 protease inhibitors wiih low nanomolar potency (10.1021/JM960586T )
- 1QBS: hiv-1 protease inhibitors wiih low nanomolar potency (10.1021/JM9602571 )
- 1QBT: hiv-1 protease inhibitors wiih low nanomolar potency (10.1021/JM960586T )
- 1QBU: hiv-1 protease inhibitors wiih low nanomolar potency (10.1021/JM960586T )
- 1RL8: crystal structure of the complex of resistant strain of hiv-1 protease(v82a mutant) with ritonavir
- 1RPI: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
- 1RQ9: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
- 1RV7: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
- 1SBG: an orally-bioavailable hiv-1 protease inhibitor containing an imidazole-derived peptide bond replacement. crystallographic and pharmacokinetic analysis (10.1021/BI00205A001 )
- 1SDT: crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site. (10.1111/J.1432-1033.2004.04060.X )
- 1SDU: crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site. (10.1111/J.1432-1033.2004.04060.X )
- 1SDV: crystal structures of hiv protease v82a and l90m mutants reveal changes in indinavir binding site. (10.1111/J.1432-1033.2004.04060.X )
- 1SP5: crystal structure of hiv-1 protease complexed with a product of autoproteolysis
- 1T3R: hiv protease wild-type in complex with tmc114 inhibitor (10.1021/JM049560P )
- 1T7I: the structural and thermodynamic basis for the binding of tmc114, a next-generation hiv-1 protease inhibitor. (10.1021/JM049560P )
- 1T7J: crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of hiv-1 protease (l63p/v82t/i84v) (10.1021/JM049560P )
- 1T7K: crystal structure of hiv protease complexed with arylsulfonamide azacyclic urea (10.1016/J.BMCL.2004.05.036 )
- 1TCX: hiv triple mutant protease complexed with inhibitor sb203386 (10.1021/BI960179J )
- 1TSU: crystal structure of decamer ncp1 substrate peptide in complex with wild-type d25n hiv-1 protease variant (10.1128/JVI.78.22.12446-12454.2004 )
- 1TW7: wide open 1.3a structure of a multi-drug resistant hiv-1 protease represents a novel drug target (10.1016/J.STR.2005.11.005 )
- 1U8G: crystal structure of a hiv-1 protease in complex with peptidomimetic inhibitor ki2-phe-glu-glu-nh2 (10.1107/S0907444904021572 )
- 1UPJ: hiv-1 protease complex with u095438 [3-[1-(4-bromophenyl) isobutyl]-4- hydroxycoumarin (10.1021/JM00018A023 )
- 1VIJ: hiv-1 protease complexed with the inhibitor hoe/bay 793 hexagonal form (10.1111/J.1432-1033.1997.00313.X )
- 1VIK: hiv-1 protease complexed with the inhibitor hoe/bay 793 orthorhombic form (10.1111/J.1432-1033.1997.00313.X )
- 1W5V: hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor (10.1111/J.1432-1033.2004.04431.X )
- 1W5W: hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor (10.1111/J.1432-1033.2004.04431.X )
- 1W5X: hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor (10.1111/J.1432-1033.2004.04431.X )
- 1W5Y: hiv-1 protease in complex with fluoro substituted diol-based c2- symmetric inhibitor (10.1111/J.1432-1033.2004.04431.X )
- 1WBK: hiv-1 protease in complex with asymmetric inhibitor, bea568
- 1WBM: hiv-1 protease in complex with symmetric inhibitor, bea450
- 1XL2: hiv-1 protease in complex with pyrrolidinmethanamine (10.1002/ANIE.200462643 )
- 1XL5: hiv-1 protease in complex with amidhyroxysulfone (10.1002/ANIE.200462643 )
- 1YT9: hiv protease with oximinoarylsulfonamide bound (10.1016/J.BMCL.2005.03.008 )
- 1YTG: siv protease crystallized with peptide product (10.1021/BI9612733 )
- 1YTH: siv protease crystallized with peptide product (10.1021/BI9612733 )
- 1Z1H: hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 3 (10.1021/BI990174X )
- 1Z1R: hiv-1 protease complexed with macrocyclic peptidomimetic inhibitor 2 (10.1021/BI990174X )
- 1Z8C: crystal structure of the complex of mutant hiv-1 protease (l63p, a71v, v82t, i84v) with a hydroxyethylamine peptidomimetic inhibitor boc- phe-psi[r-ch(oh)ch2nh]-phe-glu-phe-nh2
- 1ZBG: crystal structure of a complex of mutant hiv-1 protease (a71v, v82t, i84v) with a hydroxyethylamine peptidomimetic inhibitor boc-phe- psi[r-ch(oh)ch2nh]-phe-glu-phe-nh2
- 1ZJ7: crystal structure of a complex of mutant hiv-1 protease (a71v, v82t, i84v) with a hydroxyethylamine peptidomimetic inhibitor boc-phe- psi[s-ch(oh)ch2nh]-phe-glu-phe-nh2 (10.1021/JM0605583 )
- 1ZLF: crystal structure of a complex of mutant hiv-1 protease (a71v, v82t, i84v) with a hydroxyethylamine peptidomimetic inhibitor (10.1021/JM0605583 )
- 1ZP8: hiv protease with inhibitor ab-2 (10.1002/CBIC.200500101 )
- 1ZPA: hiv protease with scripps ab-3 inhibitor (10.1002/CBIC.200500101 )
- 1ZPK: crystal structure of the complex of mutant hiv-1 protease (a71v, v82t, i84v) with a hydroxyethylamine peptidomimetic inhibitor boc-phe- psi[r-ch(oh)ch2nh]-phe-glu-phe-nh2
- 1ZSF: crystal structure of complex of a hydroxyethylamine inhibitor with hiv-1 protease at 2.0a resolution (10.1107/S0907444906006718 )
- 1ZSR: crystal structure of wild type hiv-1 protease (bru isolate) with a hydroxyethylamine peptidomimetic inhibitor boc-phe-psi[s-ch(oh) ch2nh]-phe-glu-phe-nh2 (10.1107/S0907444906006718 )
- 1ZTZ: crystal structure of hiv protease- metallacarborane complex (10.1073/PNAS.0507577102 )
- 2A1E: high resolution structure of hiv-1 pr with ts-126 (10.1002/CMDC.200500063 )
- 2A4F: synthesis and activity of n-axyl azacyclic urea hiv-1 protease inhibitors with high potency against multiple drug resistant viral strains. (10.1016/J.BMCL.2005.08.093 )
- 2AID: structure of a non-peptide inhibitor complexed with hiv-1 protease: developing a cycle of structure-based drug design
- 2AOC: crystal structure analysis of hiv-1 protease mutant i84v with a substrate analog p2-nc (10.1111/J.1742-4658.2005.04923.X )
- 2AOD: crystal structure analysis of hiv-1 protease with a substrate analog p2-nc (10.1111/J.1742-4658.2005.04923.X )
- 2AOE: crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog ca-p2 (10.1111/J.1742-4658.2005.04923.X )
- 2AOF: crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog p1-p6 (10.1111/J.1742-4658.2005.04923.X )
- 2AOG: crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog p2-nc (10.1111/J.1742-4658.2005.04923.X )
- 2AOH: crystal structure analysis of hiv-1 protease mutant v82a with a substrate analog p6-pr (10.1111/J.1742-4658.2005.04923.X )
- 2AOI: crystal structure analysis of hiv-1 protease with a substrate analog p1-p6 (10.1111/J.1742-4658.2005.04923.X )
- 2AOJ: crystal structure analysis of hiv-1 protease with a substrate analog p6-pr (10.1111/J.1742-4658.2005.04923.X )
- 2AQU: structure of hiv-1 protease bound to atazanavir (10.1021/BI051886S )
- 2AVM: kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s (10.1016/J.JMB.2005.09.095 )
- 2AVO: kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s (10.1016/J.JMB.2005.09.095 )
- 2AVQ: kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s (10.1016/J.JMB.2005.09.095 )
- 2AVS: kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s (10.1016/J.JMB.2005.09.095 )
- 2AVV: kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s (10.1016/J.JMB.2005.09.095 )
- 2AZ8: hiv-1 protease nl4-3 in complex with inhibitor, tl-3 (10.1016/J.JMB.2005.11.094 )
- 2AZ9: hiv-1 protease nl4-3 1x mutant (10.1016/J.JMB.2005.11.094 )
- 2AZB: hiv-1 protease nl4-3 3x mutant in complex with inhibitor, tl-3 (10.1016/J.JMB.2005.11.094 )
- 2AZC: hiv-1 protease nl4-3 6x mutant (10.1016/J.JMB.2005.11.094 )
- 2BB9: structure of hiv1 protease and akc4p_133a complex. (10.1016/J.BMCL.2005.11.011 )
- 2BBB: structure of hiv1 protease and hh1_173_3a complex. (10.1016/J.BMCL.2005.11.011 )
- 2BPV: hiv-1 protease-inhibitor complex (10.1107/S0907444998003588 )
- 2BPW: hiv-1 protease-inhibitor complex (10.1107/S0907444998003588 )
- 2BPX: hiv-1 protease-inhibitor complex (10.1107/S0907444998003588 )
- 2BPY: hiv-1 protease-inhibitor complex (10.1107/S0907444998003588 )
- 2BPZ: hiv-1 protease-inhibitor complex (10.1107/S0907444998003588 )
- 2BQV: hiv-1 protease in complex with inhibitor aha455 (10.1021/JM050790T )
- 2CEJ: p1' extended hiv-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold (10.1021/JM051239Z )
- 2CEM: p1' extended hiv-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold (10.1021/JM051239Z )
- 2CEN: p1' extended hiv-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold (10.1021/JM051239Z )
- 2F3K: substrate envelope and drug resistance: crystal structure of r01 in complex with wild-type hiv-1 protease (10.1128/AAC.50.4.1518-1521.2006 )
- 2F80: hiv-1 protease mutant d30n complexed with inhibitor tmc114 (10.1021/JM050943C )
- 2F81: hiv-1 protease mutant l90m complexed with inhibitor tmc114 (10.1021/JM050943C )
- 2F8G: hiv-1 protease mutant i50v complexed with inhibitor tmc114 (10.1021/JM050943C )
- 2FDE: wild type hiv protease bound with gw0385 (10.1016/J.BMCL.2006.01.035 )
- 2FGU: x-ray crystal structure of hiv-1 protease t80s variant in complex with the inhibitor saquinavir used to explore the role of invariant thr80 in hiv-1 protease structure, function, and viral infectivity. (10.1128/JVI.01900-05 )
- 2FGV: x-ray crystal structure of hiv-1 protease t80n variant in complex with the inhibitor saquinavir used to explore the role of invariant thr80 in hiv-1 protease structure, function, and viral infectivity. (10.1128/JVI.01900-05 )
- 2FLE: structural analysis of asymmetric inhibitor bound to the hiv-1 protease v82a mutant 03-apr-07 2fle 1 title (10.1021/JM701170F )
- 2FNS: crystal structure of wild-type inactive (d25n) hiv-1 protease complexed with wild-type hiv-1 nc-p1 substrate. (10.1128/JVI.80.7.3607-3616.2006 )
- 2FXD: x-ray crystal structure of hiv-1 protease irm mutant complexed with atazanavir (bms-232632) (10.1128/JVI.02503-05 )
- 2FXE: x-ray crystal structure of hiv-1 protease crm mutant complexed with atazanavir (bms-232632) (10.1128/JVI.02503-05 )
- 2G69: structure of unliganded hiv-1 protease f53l mutant (10.1016/J.JMB.2006.02.076 )
- 2HB2: structure of hiv protease 6x mutant in apo form (10.1107/S0907444907029125 )
- 2HB3: wild-type hiv-1 protease in complex with potent inhibitor grl06579 (10.1021/JM060561M )
- 2HB4: structure of hiv protease nl4-3 in an unliganded state (10.1107/S0907444907029125 )
- 2HC0: structure of hiv protease 6x mutant in complex with ab-2.
- 2HS1: ultra-high resolution x-ray crystal structure of hiv-1 protease v32i mutant with tmc114 (darunavir) inhibitor (10.1016/J.JMB.2006.08.007 )
- 2HS2: crystal structure of m46l mutant of hiv-1 protease complexed with tmc114 (darunavir) (10.1016/J.JMB.2006.08.007 )
- 2HVP: three-dimensional structure of aspartyl protease from human immunodeficiency virus hiv-1 (10.1038/337615A0 )
- 2I0A: crystal structure of kb-19 complexed with wild type hiv-1 protease (10.1021/JM060666P )
- 2I0D: crystal structure of ad-81 complexed with wild type hiv-1 protease (10.1021/JM060666P )
- 2I4D: crystal structure of wt hiv-1 protease with gs-8373 (10.1016/J.JMB.2006.07.073 )
- 2I4U: hiv-1 protease with tmc-126 (10.1016/J.JMB.2006.07.073 )
- 2I4V: hiv-1 protease i84v, l90m with tmc126 (10.1016/J.JMB.2006.07.073 )
- 2I4W: hiv-1 protease wt with gs-8374 (10.1016/J.JMB.2006.07.073 )
- 2I4X: hiv-1 protease i84v, l90m with gs-8374 (10.1016/J.JMB.2006.07.073 )
- 2IDW: crystal structure analysis of hiv-1 protease mutant v82a with a potent non-peptide inhibitor (uic-94017) (10.1016/J.JMB.2004.02.052 )
- 2IEN: crystal structure analysis of hiv-1 protease with a potent non-peptide inhibitor (uic-94017) (10.1016/J.JMB.2004.02.052 )
- 2IEO: crystal structure analysis of hiv-1 protease mutant i84v with a potent non-peptide inhibitor (uic-94017) (10.1016/J.JMB.2004.02.052 )
- 2NMY: crystal structure analysis of hiv-1 protease mutant v82a with a inhibitor saquinavir (10.1002/PROT.21304 )
- 2NMZ: crystal structure analysis of hiv-1 protease mutant v82a with a inhibitor saquinavir (10.1002/PROT.21304 )
- 2NNK: crystal structure analysis of hiv-1 protease mutant i84v with a inhibitor saquinavir (10.1002/PROT.21304 )
- 2NNP: crystal structure analysis of hiv-1 protease mutant i84v with a inhibitor saquinavir (10.1002/PROT.21304 )
- 2NPH: crystal structure of hiv1 protease in situ product complex (10.1073/PNAS.0605809103 )
- 2NXD: structure of hiv-1 protease d25n complexed with rt-rh analogue peptide gly-ala-asp-ile-phe*tyr-leu-asp-gly-ala (10.1002/PROT.21514 )
- 2NXL: structure of hiv-1 protease d25n complexed with the rt-rh analogue peptide gly-ala-glu-val-phe*tyr-val-asp-gly-ala (10.1002/PROT.21514 )
- 2NXM: structure of hiv-1 protease d25n complexed with the rt-rh analogue peptide gly-ala-gln-thr-phe*tyr-val-asp-gly-ala (10.1002/PROT.21514 )
- 2O4K: crystal structure of hiv-1 protease (q7k) in complex with atazanavir (10.1128/JVI.02706-06 )
- 2O4L: crystal structure of hiv-1 protease (q7k, i50v) in complex with tipranavir (10.1128/JVI.02706-06 )
- 2O4N: crystal structure of hiv-1 protease (trm mutant) in complex with tipranavir (10.1128/JVI.02706-06 )
- 2O4P: crystal structure of hiv-1 protease (q7k) in complex with tipranavir (10.1128/JVI.02706-06 )
- 2O4S: crystal structure of hiv-1 protease (q7k) in complex with lopinavir (10.1128/JVI.02706-06 )
- 2P3B: crystal structure of the subtype b wild type hiv protease complexed with tl-3 inhibitor (10.1016/J.JMB.2007.03.049 )
- 2PC0: apo wild-type hiv protease in the open conformation (10.1107/S0907444907029125 )
- 2PK5: crystal structure of hiv-1 protease (q7k, l33i, l63i ) in complex with kni-10075 (10.1111/J.1747-0285.2007.00519.X )
- 2PK6: crystal structure of hiv-1 protease (q7k, l33i, l63i) in complex with kni-10033 (10.1111/J.1747-0285.2007.00519.X )
- 2PQZ: hiv-1 protease in complex with a pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2PSU: crystal structure of wild type hiv-1 protease in complex with carb- ad37 (10.1111/J.1747-0285.2007.00514.X )
- 2PSV: crystal structure of wild type hiv-1 protease in complex with carb- kb45 (10.1111/J.1747-0285.2007.00514.X )
- 2PWC: hiv-1 protease in complex with a amino decorated pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2PWR: hiv-1 protease in complex with a carbamoyl decorated pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2PYM: hiv-1 pr mutant in complex with nelfinavir (10.1016/J.JMB.2007.09.083 )
- 2PYN: hiv-1 pr mutant in complex with nelfinavir (10.1016/J.JMB.2007.09.083 )
- 2Q3K: crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in hiv-1 protease (10.1128/JVI.00799-07 )
- 2Q54: crystal structure of kb73 bound to hiv-1 protease (10.1021/JM070284Z )
- 2Q55: crystal structure of kk44 bound to hiv-1 protease (10.1021/JM070284Z )
- 2Q5K: crystal structure of lopinavir bound to wild type hiv-1 protease (10.1021/JM070284Z )
- 2Q63: hiv-1 pr mutant in complex with nelfinavir (10.1016/J.JMB.2007.09.083 )
- 2Q64: hiv-1 pr mutant in complex with nelfinavir (10.1016/J.JMB.2007.09.083 )
- 2QAK: hiv-1 pr mutant in complex with nelfinavir
- 2QCI: hiv-1 protease mutant d30n with potent antiviral inhibitor grl-98065 (10.1021/JM070482Q )
- 2QD6: hiv-1 protease mutant i50v with potent antiviral inhibitor grl-98065 (10.1021/JM070482Q )
- 2QD7: hiv-1 protease mutant v82a with potent antiviral inhibitor grl-98065 (10.1021/JM070482Q )
- 2QD8: hiv-1 protease mutant i84v with potent antiviral inhibitor grl-98065 (10.1021/JM070482Q )
- 2QHC: the influence of i47a mutation on reduced susceptibility to the protease inhibitor lopinavir (10.1110/PS.036079.108 )
- 2QHY: crystal structure of protease inhibitor, mit-1-ac86 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QHZ: crystal structure of protease inhibitor, mit-1-ac87 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI0: crystal structure of protease inhibitor, mit-1-kk80 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI1: crystal structure of protease inhibitor, mit-1-kk81 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI3: crystal structure of protease inhibitor, mit-2-ad94 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI4: crystal structure of protease inhibitor, mit-2-ad93 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI5: crystal structure of protease inhibitor, mit-2-kc08 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI6: crystal structure of protease inhibitor, mit-2-kb98 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QI7: crystal structure of protease inhibitor, mit-2-ad86 in complex with wild type hiv-1 protease (10.1021/JA076558P )
- 2QMP: crystal structure of hiv-1 protease complexed with pl-100
- 2QNN: hiv-1 protease in complex with a multiple decorated pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2QNP: hiv-1 protease in complex with a iodo decorated pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2QNQ: hiv-1 protease in complex with a chloro decorated pyrrolidine-based inhibitor (10.1021/JM701142S )
- 2R38: i84v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor (10.1016/J.JMB.2008.07.062 )
- 2R3T: i50v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor (10.1016/J.JMB.2008.07.062 )
- 2R3W: i84v hiv-1 protease in complex with a amino decorated pyrrolidine-based inhibitor (10.1016/J.JMB.2008.07.062 )
- 2R43: i50v hiv-1 protease in complex with an amino decorated pyrrolidine- based inhibitor (10.1016/J.JMB.2008.07.062 )
- 2R5P: crystal structure analysis of hiv-1 subtype c protease complexed with indinavir (10.1021/BI7018332 )
- 2R5Q: crystal structure analysis of hiv-1 subtype c protease complexed with nelfinavir (10.1021/BI7018332 )
- 2R8N: structural analysis of the unbound form of hiv-1 subtype c protease (10.1107/S090744490801278X )
- 2UPJ: hiv-1 protease complex with u100313 ([3-[[3-[cyclopropyl [4-hydroxy- 2oxo-6-[1-(phenylmethyl)propyl]-2h-pyran-3-yl] methyl]phenyl]amino]- 3-oxo-propyl]carbamic acid tert-butyl ester) (10.1021/JM00018A023 )
- 2UXZ: two-carbon-elongated hiv-1 protease inhibitors with a tertiary- alcohol-containing transition-state mimic (10.1021/JM070680H )
- 2UY0: two-carbon-elongated hiv-1 protease inhibitors with a tertiary- alcohol-containing transition-state mimic (10.1021/JM070680H )
- 2WKZ: hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity (10.1021/JM901165G )
- 2WL0: hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity (10.1021/JM901165G )
- 2XYE: hiv-1 inhibitors with a tertiary-alcohol-containing transition-state mimic and various p2 and p1 prime substituents (10.1039/C1MD00077B )
- 2XYF: hiv-1 inhibitors with a tertiary-alcohol-containing transition-state mimic and various p2 and p1 prime substituents (10.1039/C1MD00077B )
- 2Z4O: wild type hiv-1 protease with potent antiviral inhibitor grl-98065 (10.1021/JM070482Q )
- 2Z54: the influence of i47a mutation on reduced susceptibility to the protease inhibitor lopinavir (10.1110/PS.036079.108 )
- 2ZGA: hiv-1 protease in complex with a dimethylallyl decorated pyrrolidine based inhibitor (hexagonal space group) (10.1016/J.JMB.2011.04.052 )
- 2ZYE: structure of hiv-1 protease in complex with potent inhibitor kni-272 determined by neutron crystallography (10.1073/PNAS.0809400106 )
- 3A2O: crystal structure of hiv-1 protease complexed with kni-1689 (10.1021/JM9005115 )
- 3AID: a new class of hiv-1 protease inhibitor: the crystallographic structure, inhibition and chemical synthesis of an aminimide peptide isostere (10.1016/0968-0896(96)00147-2 )
- 3B7V: hiv-1 protease complexed with gem-diol-amine tetrahedral intermediate nlltqi (10.1021/BI700822G )
- 3B80: hiv-1 protease mutant i54v complexed with gem-diol-amine intermediate nlltqi (10.1021/BI700822G )
- 3BC4: i84v hiv-1 protease in complex with a pyrrolidine diester (10.1002/CMDC.200800113 )
- 3BGB: hiv-1 protease in complex with a isobutyl decorated oligoamine (10.1016/J.BMC.2008.08.012 )
- 3BGC: hiv-1 protease in complex with a benzyl decorated oligoamine (10.1016/J.BMC.2008.08.012 )
- 3BHE: hiv-1 protease in complex with a three armed pyrrolidine derivative
- 3BVA: cystal structure of hiv-1 active site mutant d25n and p2-nc analog inhibitor (10.1074/JBC.M708506200 )
- 3BVB: cystal structure of hiv-1 active site mutant d25n and inhibitor darunavir (10.1074/JBC.M708506200 )
- 3BXS: crystal structures of highly constrained substrate and hydrolysis products bound to hiv-1 protease. implications for catalytic mechanism (10.1021/BI7023157 )
- 3CKT: hiv-1 protease in complex with a dimethylallyl decorated pyrrolidine based inhibitor (orthorombic space group) (10.1016/J.JMB.2011.04.052 )
- 3CYW: effect of flap mutations on structure of hiv-1 protease and inhibition by saquinavir and darunavir (10.1016/J.JMB.2008.05.062 )
- 3CYX: crystal structure of hiv-1 mutant i50v and inhibitor saquinavira (10.1016/J.JMB.2008.05.062 )
- 3D1X: crystal structure of hiv-1 mutant i54m and inhibitor saquinavir (10.1016/J.JMB.2008.05.062 )
- 3D1Y: crystal structure of hiv-1 mutant i54v and inhibitor saquina (10.1016/J.JMB.2008.05.062 )
- 3D1Z: crystal structure of hiv-1 mutant i54m and inhibitor darunavir (10.1016/J.JMB.2008.05.062 )
- 3D20: crystal structure of hiv-1 mutant i54v and inhibitor darunavia (10.1016/J.JMB.2008.05.062 )
- 3D3T: crystal structure of hiv-1 crf01_ae in complex with the substrate p1- p6 (10.1128/JVI.00018-08 )
- 3DJK: wild type hiv-1 protease with potent antiviral inhibitor grl-0255a (10.1021/JM8004543 )
- 3DK1: wild type hiv-1 protease with potent antiviral inhibitor grl-0105a (10.1039/B809178A )